Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Clinical trial NCT06484153 · RECRUITING

Trial details

NCT number: NCT06484153
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer

Start date: 2024-07-22
Primary completion: 2026-07-22
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.